Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DTR 3.1.4R
We hereby inform you that on 27 March 2009 the following individuals, who are all persons discharging managerial responsibilities, were granted options under the AstraZeneca Share Option Plan over the Company's USD0.25 Ordinary Shares or, in the case of L Tetrault and A Zook, over the Company's American Depositary Shares (ADSs). One ADS equals one Ordinary Share
Name of individual |
Number of shares over which option is granted |
Exercise price per share |
Period when exercisable |
B Angelici |
40,964 |
2280p |
27.3.12-26.3.19 |
A Ekblom |
30,180 |
2280p |
27.3.12-26.3.19 |
J Lundberg |
41,668 |
2280p |
27.3.12-26.3.19 |
J Pott |
30,701 |
2280p |
27.3.12-26.3.19 |
D Smith |
33,333 |
2280p |
27.3.12-26.3.19 |
L Tetrault |
73,926 |
US$33.39 |
27.3.12-26.3.19 |
A Zook |
113,638 |
US$33.39 |
27.3.12-26.3.19 |
The options will become exercisable on 27 March 2012 subject to certain performance conditions. The conditions, which will not be subject to any retesting, are that the earnings per share of the Company must increase by the increase in the UK Retail Prices Index plus 5% per annum on average over three years, and that no significant unforeseen event has taken place which, in the reasonable opinion of the Remuneration Committee, has resulted in major reputational damage to AstraZeneca, and the circumstances of which are exceptional enough to justify the option not vesting and becoming exercisable. Failure to satisfy either or both of these conditions will result in the lapse of the option in its entirety.
A C N Kemp
Company Secretary
30 March 2009